Physician profile
Amy Calati
NPI 1942612577
$1,358.86
in general payments reported to CMS, 2019-2025
18 companies · $14.63 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2021: $90.86 · 2022: $150 · 2023: $91.14 · 2024: $14.08 · 2025: $14.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $119.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $290.55 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Alexion Pharmaceuticals, INC. | $176.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $161.20 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $145.47 | 2019-2023 | Tagrisso |
| Novartis Pharmaceuticals Corporation | $113.56 | 2019-2023 | |
| Seagen INC. | $101.40 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $73.48 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $46.98 | 2019 | |
| Astellas Pharma US INC | $37.45 | 2019-2022 | |
| Genentech USA, INC. | $36.41 | 2022-2024 | Alecensa, Rozlytrek, Tecentriq |
| Genzyme Corporation | $35.01 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $28.84 | 2022 | |
| Pfizer INC. | $26.04 | 2019 | |
| Taiho Oncology, INC. | $19.96 | 2019 | |
| Recordati_rare_diseases_inc. | $19.85 | 2023 | Sylvant |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $17.23 | 2019 | |
| Gilead Sciences, INC. | $14.80 | 2023 | |
| Glaxosmithkline, LLC. | $14.63 | 2025 | Jemperli, Zejula |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Calati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.